Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: Boosting autoimmunity to fight-off chronic neuroinflammation

Journal of Autoimmunity

Volumn 54, Issue , 2014, Pages 8-14

  Schwartz, Michal ^a   Baruch, Kuti ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Autoimmunity; Neurodegenerative diseases; Neuroinflammation

Indexed keywords

BETA1A INTERFERON; BRAIN ANTIGEN; GLATIRAMER; IMMUNOGLOBULIN; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; AUTOANTIGEN;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; B LYMPHOCYTE; BRAIN INJURY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MEMORY; MENTAL STRESS; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SPATIAL LEARNING; SPINAL CORD INJURY; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ACUTE DISEASE; ANIMAL; BRAIN; CHRONIC DISEASE; IMMUNOLOGY; MULTIPLE SCLEROSIS; PATHOLOGY; SPINAL CORD;

ACUTE DISEASE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AUTOANTIGENS; BRAIN; CHRONIC DISEASE; HUMANS; IMMUNE TOLERANCE; MULTIPLE SCLEROSIS; SPINAL CORD; T-LYMPHOCYTES, REGULATORY;

EID: 84908365146     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.08.002     Document Type: Review

References (96)

1. Burns J., Rosenzweig A., Zweiman B., Lisak R.P. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983, 81:435-440.
2. Mor F., Cohen I.R. How special is a pathogenic CNS autoantigen? Immunization to many CNS self-antigens does not induce autoimmune disease. JNeuroimmunol 2006, 174:3-11.
3. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999, 5:49-55.
4. Hauben E., Agranov E., Gothilf A., Nevo U., Cohen A., Smirnov I., et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. JClin Invest 2001, 108:591-599.
5. Hauben E., Butovsky O., Nevo U., Yoles E., Moalem G., Agranov E., et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. JNeurosci 2000, 20:6421-6430.
6. Ziv Y., Ron N., Butovsky O., Landa G., Sudai E., Greenberg N., et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 2006, 9:268-275.
7. Hendrix S., Nitsch R. The role of T helper cells in neuroprotection and regeneration. JNeuroimmunol 2007, 184:100-112.
8. Hofstetter H.H., Sewell D.L., Liu F., Sandor M., Forsthuber T., Lehmann P.V., et al. Autoreactive T cells promote post-traumatic healing in the central nervous system. JNeuroimmunol 2003, 134:25-34.
9. Olsson T., Lidman O., Piehl F. Harm or heal-divergent effects of autoimmune neuroinflammation?. Trends Immunol 2003, 24:5-6. author reply 7-8.
10. Kipnis J., Mizrahi T., Yoles E., Ben-Nun A., Schwartz M. Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. JNeuroimmunol 2002, 130:78-85.
11. + T cells are sufficient to support learning behavior in mice with limited T cell repertoire. Brain Behav Immun 2014, 35:58-63.
12. Yoles E., Hauben E., Palgi O., Agranov E., Gothilf A., Cohen A., et al. Protective autoimmunity is a physiological response to CNS trauma. JNeurosci 2001, 21:3740-3748.
13. Schori H., Lantner F., Shachar I., Schwartz M. Severe immunodeficiency has opposite effects on neuronal survival in glutamate-susceptible and -resistant mice: adverse effect of B cells. JImmunol 2002, 169:2861-2865.
14. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., et al. Tcell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000, 97:7446-7451.
15. Hauben E., Nevo U., Yoles E., Moalem G., Agranov E., Mor F., et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet 2000, 355:286-287.
16. Fisher J., Levkovitch-Verbin H., Schori H., Yoles E., Butovsky O., Kaye J.F., et al. Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. JNeurosci 2001, 21:136-142.
17. Hammarberg H., Lidman O., Lundberg C., Eltayeb S.Y., Gielen A.W., Muhallab S., et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. JNeurosci 2000, 20:5283-5291.
18. Schwartz M., Kipnis J. Autoimmunity on alert: naturally occurring regulatory CD4(+)CD25(+) T cells as part of the evolutionary compromise between a 'need' and a 'risk'. Trends Immunol 2002, 23:530-534.
19. Schwartz M., Raposo C. Protective autoimmunity: a unifying model for the immune network involved in CNS repair. Neuroscientist 2014, 20:343-358.
20. Wolf S.A., Fisher J., Bechmann I., Steiner B., Kwidzinski E., Nitsch R. Neuroprotection by T-cells depends on their subtype and activation state. JNeuroimmunol 2002, 133:72-80.
21. Shechter R., London A., Varol C., Raposo C., Cusimano M., Yovel G., et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009, 6. e1000113.
22. Nahrendorf M., Swirski F.K., Aikawa E., Stangenberg L., Wurdinger T., Figueiredo J.L., et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. JExp Med 2007, 204:3037-3047.
23. Arnold L., Henry A., Poron F., Baba-Amer Y., van Rooijen N., Plonquet A., et al. Inflammatory monocytes recruited after skeletal muscle injury switch into anti inflammatory macrophages to support myogenesis. JExp Med 2007, 204:1057-1069.
24. London A., Itskovich E., Benhar I., Kalchenko V., Mack M., Jung S., et al. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. JExp Med 2011, 208:23-39.
25. Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
26. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.
27. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A 2006, 103:11784-11789.
28. Butovsky O., Ziv Y., Schwartz A., Landa G., Talpalar A.E., Pluchino S., et al. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci 2006, 31:149-160.
29. Schori H., Kipnis J., Yoles E., WoldeMussie E., Ruiz G., Wheeler L.A., et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A 2001, 98:3398-3403.
30. Butovsky O., Talpalar A.E., Ben-Yaakov K., Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci 2005, 29:381-393.
31. Garg S.K., Banerjee R., Kipnis J. Neuroprotective immunity: T cell-derived glutamate endows astrocytes with a neuroprotective phenotype. JImmunol 2008, 180:3866-3873.
32. Shaked I., Tchoresh D., Gersner R., Meiri G., Mordechai S., Xiao X., et al. Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. JNeurochem 2005, 92:997-1009.
33. Butovsky O., Kunis G., Koronyo-Hamaoui M., Schwartz M. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur J Neurosci 2007, 26:413-416.
34. Lledo P.M., Alonso M., Grubb M.S. Adult neurogenesis and functional plasticity in neuronal circuits. Nat Rev Neurosci 2006, 7:179-193.
35. Kipnis J., Gadani S., Derecki N.C. Pro-cognitive properties of T cells. Nat Rev Immunol 2012, 12:663-669.
36. Schwartz M., Ziv Y. Immunity to self and self-maintenance: a unified theory of brain pathologies. Trends Immunol 2008, 29:211-219.
37. Kipnis J., Cohen H., Cardon M., Ziv Y., Schwartz M. Tcell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc Natl Acad Sci U S A 2004, 101:8180-8185.
38. Ron-Harel N., Segev Y., Lewitus G.M., Cardon M., Ziv Y., Netanely D., et al. Age-dependent spatial memory loss can be partially restored by immune activation. Rejuvenation Res 2008, 11:903-913.
39. Baruch K., Ron-Harel N., Gal H., Deczkowska A., Shifrut E., Ndifon W., et al. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc Natl Acad Sci U S A 2013, 110:2264-2269.
40. Wolf S.A., Steiner B., Akpinarli A., Kammertoens T., Nassenstein C., Braun A., et al. CD4-positive T lymphocytes provide a neuro immunological link in the control of adult hippocampal neurogenesis. JImmunol 2009, 182:3979-3984.
41. Derecki N.C., Cardani A.N., Yang C.H., Quinnies K.M., Crihfield A., Lynch K.R., et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. JExp Med 2010, 207:1067-1080.
42. Shechter R., Ziv Y., Schwartz M. New GABAergic interneurons supported by myelin-specific T cells are formed in intact adult spinal cord. Stem cells 2007, 25:2277-2282.
43. Shechter R., Baruch K., Schwartz M., Rolls A. Touch gives new life: mechanosensation modulates spinal cord adult neurogenesis. Mol Psychiatr 2011, 16:342-352.
44. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
45. Ekdahl C.T., Kokaia Z., Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009, 158:1021-1029.
46. Rolls A., Shechter R., Schwartz M. The bright side of the glial scar in CNS repair. Nat Rev Neurosci 2009, 10:235-241.
47. Baruch K., Schwartz M. CNS-specific T cells shape brain function via the choroid plexus. Brain Behav Immun 2013, 34:11-16.
48. Rook G.A., Lowry C.A., Raison C.L. Lymphocytes in neuroprotection, cognition and emotion: is intolerance really the answer?. Brain Behav Immun 2011, 25:591-601.
49. Johanson C.E., Stopa E.G., McMillan P.N. The blood-cerebrospinal fluid barrier: structure and functional significance. Methods Mol biology 2011, 686:101-131.
50. Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 2011, 8:3.
51. Provencio J.J., Kivisakk P., Tucky B.H., Luciano M.G., Ransohoff R.M. Comparison of ventricular and lumbar cerebrospinal fluid T cells in non-inflammatory neurological disorder (NIND) patients. JNeuroimmunol 2005, 163:179-184.
52. Kivisakk P., Mahad D.J., Callahan M.K., Trebst C., Tucky B., Wei T., et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A 2003, 100:8389-8394.
53. Carrithers M.D., Visintin I., Viret C., Janeway C.S. Role of genetic background in P selectin-dependent immune surveillance of the central nervous system. JNeuroimmunol 2002, 129:51-57.
54. Kunis G., Baruch K., Rosenzweig N., Kertser A., Miller O., Berkutzki T., et al. IFN-gamma-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair. Brain 2013, 136:3427-3440.
55. Steffen B.J., Breier G., Butcher E.C., Schulz M., Engelhardt B. ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes invitro. Am J Pathol 1996, 148:1819-1838.
56. Shechter R., Miller O., Yovel G., Rosenzweig N., London A., Ruckh J., et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 2013, 38:555-569.
57. Carrithers M.D., Visintin I., Kang S.J., Janeway C.A. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000, 123(Pt 6):1092-1101.
58. Szmydynger-Chodobska J., Strazielle N., Zink B.J., Ghersi-Egea J.F., Chodobski A. The role of the choroid plexus in neutrophil invasion after traumatic brain injury. JCereb Blood Flow Metab 2009, 29:1503-1516.
59. Szmydynger-Chodobska J., Strazielle N., Gandy J.R., Keefe T.H., Zink B.J., Ghersi-Egea J.F., et al. Posttraumatic invasion of monocytes across the blood-cerebrospinal fluid barrier. JCereb Blood Flow Metab 2012, 32:93-104.
60. Raposo C., Graubardt N., Cohen M., Eitan C., London A., Berkutzki T., et al. CNS repair requires both effector and regulatory T cells with distinct temporal and spatial profiles. JNeurosci 2014, 34:10141-10155.
61. Shechter R., London A., Schwartz M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat Rev Immunol 2013, 13:206-218.
62. Gordon L.B., Nolan S.C., Ksander B.R., Knopf P.M., Harling-Berg C.J. Normal cerebrospinal fluid suppresses the invitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation. JNeuroimmunol 1998, 88:77-84.
63. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006, 60:22-31.
64. Fondell E., O'Reilly E.J., Fitzgerald K.C., Falcone G.J., McCullough M.L., Thun M.J., et al. Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph Lateral Scler 2012, 13:573-579.
65. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053.
66. Wolinsky J.S., Narayana P.A., O'Connor P., Coyle P.K., Ford C., Johnson K., et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007, 61:14-24.
67. Schwartz M., Ziv Y. Immunity to self and self-maintenance: what can tumor immunology teach us about ALS and Alzheimer's disease?. Trends Pharmacol Sci 2008, 29:287-293.
68. Teng M.W., Swann J.B., Koebel C.M., Schreiber R.D., Smyth M.J. Immune-mediated dormancy: an equilibrium with cancer. JLeukoc Biol 2008, 84:988-993.
69. + T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A 2008, 105:15558-15563.
70. Panossian L.A., Porter V.R., Valenzuela H.F., Zhu X., Reback E., Masterman D., et al. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging 2003, 24:77-84.
71. Chou J.P., Effros R.B. Tcell replicative senescence in human aging. Curr Pharm Des 2013, 19:1680-1698.
72. Eitan E., Tichon A., Gazit A., Gitler D., Slavin S., Priel E. Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. EMBO Mol Med 2012, 4:313-329.
73. Schwartz M., Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J 2014, 33:7-22.
74. Conlon P., Steinman L. Altered peptide ligands and MS treatment. Science 2002, 296:1801-1802. author reply-2.
75. Haas J., Korporal M., Balint B., Fritzsching B., Schwarz A., Wildemann B. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. JNeuroimmunol 2009, 216:113-117.
76. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013, 12:543-553.
77. Angelov D.N., Waibel S., Guntinas-Lichius O., Lenzen M., Neiss W.F., Tomov T.L., et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2003, 100:4790-4795.
78. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 2005, 102:6449-6454.
79. Weber M.S., Hohlfeld R., Zamvil S.S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007, 4:647-653.
80. Bakalash S., Ben-Shlomo G., Aloni E., Shaked I., Wheeler L., Ofri R., et al. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. JMol Med 2005, 83:904-916.
81. Grimaldi L.M., Zappala G., Iemolo F., Castellano A.E., Ruggieri S., Bruno G., et al. Apilot study on the use of interferon beta-1a in early Alzheimer's disease subjects. JNeuroinflammation 2014, 11:30.
82. Beghi E., Chio A., Inghilleri M., Mazzini L., Micheli A., Mora G., et al. Arandomized controlled trial of recombinant interferon beta-1a in ALS. Italian amyotrophic lateral sclerosis study group. Neurology 2000, 54:469-474.
83. Meininger V., Drory V.E., Leigh P.N., Ludolph A., Robberecht W., Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009, 10:378-383.
84. Zhang Y., Metz L.M., Yong V.W., Bell R.B., Yeung M., Patry D.G., et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurological Sci Le J Can Des Sci Neurologiques 2008, 35:185-191.
85. Zabad R.K., Metz L.M., Todoruk T.R., Zhang Y., Mitchell J.R., Yeung M., et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007, 13:517-526.
86. Sorensen P.S., Wanscher B., Jensen C.V., Schreiber K., Blinkenberg M., Ravnborg M., et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998, 50:1273-1281.
87. Achiron A., Gabbay U., Gilad R., Hassin-Baer S., Barak Y., Gornish M., et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998, 50:398-402.
88. Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G., Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian immunoglobulin in multiple sclerosis study group. Lancet 1997, 349:589-593.
89. Fazekas F., Lublin F.D., Li D., Freedman M.S., Hartung H.P., Rieckmann P., et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008, 71:265-271.
90. Loeffler D.A. Intravenous immunoglobulin and Alzheimer's disease: what now?. JNeuroinflammation 2013, 10:70.
91. Dodel R., Rominger A., Bartenstein P., Barkhof F., Blennow K., Forster S., et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013, 12:233-243.
92. Rio J., Nos C., Bonaventura I., Arroyo R., Genis D., Sureda B., et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004, 63:525-528.
93. Pollmann W., Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008, 22:291-324.
94. Breitner J.C., Haneuse S.J., Walker R., Dublin S., Crane P.K., Gray S.L., et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009, 72:1899-1905.
95. Arvanitakis Z., Grodstein F., Bienias J.L., Schneider J.A., Wilson R.S., Kelly J.F., et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008, 70:2219-2225.
96. Group A.R., Martin B.K., Szekely C., Brandt J., Piantadosi S., Breitner J.C., et al. Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008, 65:896-905.